Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc. and was filed in the District of Massachusetts [1]. - Investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, have until June 16, 2025, to seek lead plaintiff status [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. Group 2: Financial Impact - Zenas BioPharma sold over 13 million shares at 8.72, representing a 48.7% decline from the IPO price [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing the investors in the class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone [6].
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. (ZBIO) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit